Roivant Sciences, Cigna Ventures and Johnson & Johnson Innovation – JJDC helped push the healthcare data exchange's overall funding to $83m.
US-based medical data exchange technology developer Datavant has received $40m in series B funding from investors including corporates Roivant Sciences, Johnson & Johnson and Cigna.
Transformation Capital led the round, which included Flex Capital along with biopharmaceutical holding company Roivant Sciences, healthcare product supplier Johnson & Johnson and health insurer Cigna, through Johnson & Johnson Innovation – JJDC and Cigna Ventures respectively.
Founded in 2017, Datavant has built a healthcare data exchange enabling clinical trial centres to compare their study…